用于中低收入国家的 COVID-19 疫苗。
COVID-19 vaccines for low- and middle-income countries.
机构信息
Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, WC1E 7HT, UK.
出版信息
Trans R Soc Trop Med Hyg. 2021 May 8;115(5):447-456. doi: 10.1093/trstmh/trab045.
Abstract
The COVID-19 pandemic is the biggest threat to public health in a century. Through hard work and ingenuity, scientists have developed a number of safe and effective vaccines against COVID-19 disease. However, demand far outstrips supply and countries around the world are competing for available vaccines. This review describes how low- and middle-income countries access COVID-19 vaccines, what is being done to distribute vaccines fairly, as well as the challenges ahead.
摘要
新冠疫情是本世纪对公共卫生的最大威胁。通过努力和创新，科学家们已经开发出了一些针对 COVID-19 疾病的安全有效的疫苗。然而，需求远远超过供应，全球各国正在争夺可用的疫苗。这篇综述描述了低收入和中等收入国家如何获得 COVID-19 疫苗，正在采取什么措施公平分配疫苗，以及未来的挑战。
相似文献
1
COVID-19 vaccines for low- and middle-income countries.用于中低收入国家的 COVID-19 疫苗。
Trans R Soc Trop Med Hyg. 2021 May 8;115(5):447-456. doi: 10.1093/trstmh/trab045.
2
COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs.COVID-19 疫苗和治疗的民族主义：对低收入国家和实现可持续发展目标的挑战。
Glob Public Health. 2021 Mar;16(3):319-339. doi: 10.1080/17441692.2020.1860249. Epub 2020 Dec 15.
3
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.SARS-CoV-2 变体和 COVID-19 疫苗：当前的挑战与未来策略。
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
4
Transforming COVID-19 vaccines into vaccination : Challenges and opportunities for management scientists.将 COVID-19 疫苗转化为接种疫苗：管理科学家面临的挑战和机遇。
Health Care Manag Sci. 2021 Sep;24(3):455-459. doi: 10.1007/s10729-021-09563-3. Epub 2021 Jun 16.
5
Vaccines for COVID-19: Where do we stand in 2021?2021 年的 COVID-19 疫苗：我们处于什么阶段？
Paediatr Respir Rev. 2021 Sep;39:22-31. doi: 10.1016/j.prrv.2021.07.001. Epub 2021 Jul 12.
6
International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility.国际合作确保公平获取 COVID-19 疫苗：ACT-Accelerator 和 COVAX 设施。
Milbank Q. 2021 Jun;99(2):426-449. doi: 10.1111/1468-0009.12503. Epub 2021 Mar 2.
7
Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics.低收入和中等收入国家对新冠病毒疫苗及治疗方法的迫切需求。
Lancet. 2021 Feb 13;397(10274):562-564. doi: 10.1016/S0140-6736(21)00242-7. Epub 2021 Jan 28.
8
Equitable and Feasible Distribution of SARS-CoV-2 Vaccines for All in Africa.在非洲为所有人公平且可行地分配 SARS-CoV-2 疫苗。
Am J Trop Med Hyg. 2021 Jun 28;105(2):278-280. doi: 10.4269/ajtmh.21-0264.
9
COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far.COVID-19：具有悠久历史、流行病学和迄今进展的全球性挑战。
Molecules. 2020 Dec 23;26(1):39. doi: 10.3390/molecules26010039.
10
COVID-19 vaccine challenges: What have we learned so far and what remains to be done?COVID-19 疫苗面临的挑战：到目前为止我们了解到了什么，还有什么需要做？
Health Policy. 2021 May;125(5):553-567. doi: 10.1016/j.healthpol.2021.03.013. Epub 2021 Mar 26.
引用本文的文献
1
Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique.BBIBP-CorV和Ad26.COV2.S新冠疫苗异源与同源初免-加强免疫方案的免疫原性和安全性：在马达加斯加和莫桑比克进行的一项多中心、随机、观察者盲法非劣效性试验
Clin Infect Dis. 2025 Jul 22;80(Supplement_1):S37-S46. doi: 10.1093/cid/ciaf130.
2
The impact of vaccine booster doses on specific B- and T-lymphocyte dynamics in Thai healthcare personnel following COVID-19 vaccination.新冠疫苗接种后，加强针剂量对泰国医护人员特定B淋巴细胞和T淋巴细胞动态变化的影响
Sci Rep. 2025 Jul 16;15(1):25713. doi: 10.1038/s41598-025-10400-8.
3
Lesson learnt from the COVID-19 pandemic: a qualitative inquiry into patient and family experiences in Pakistan.从新冠疫情中吸取的教训：对巴基斯坦患者及家属经历的质性探究
BMJ Open. 2025 Mar 12;15(3):e084175. doi: 10.1136/bmjopen-2024-084175.
4
Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial.Ad26.COV2.S在青少年中的安全性和免疫原性：2期随机临床试验。
Hum Vaccin Immunother. 2025 Dec;21(1):2450120. doi: 10.1080/21645515.2025.2450120. Epub 2025 Jan 27.
5
Pfizer-BioNTech (BNT162b2) Vaccine Effectiveness against Symptomatic Laboratory-Confirmed COVID-19 Infection among Outpatients in Sentinel Sites, Lebanon, July-December 2021.2021年7月至12月，黎巴嫩哨点地区门诊患者中辉瑞-生物科技公司（BNT162b2）疫苗对实验室确诊的有症状COVID-19感染的有效性
Vaccines (Basel). 2024 Aug 23;12(9):954. doi: 10.3390/vaccines12090954.
6
Correlating COVID-19 severity with biomarker profiles and patient prognosis.将 COVID-19 严重程度与生物标志物谱和患者预后相关联。
Sci Rep. 2024 Sep 27;14(1):22353. doi: 10.1038/s41598-024-71951-w.
7
Immunogenicity of COVID-19 adsorbed inactivated vaccine (CoronaVac) and additional doses of mRNA BNT162b2 vaccine in immunocompromised adults compared with immunocompetent persons.与免疫功能正常者相比，新冠病毒吸附灭活疫苗（科兴疫苗）及额外剂量的mRNA BNT162b2疫苗在免疫功能低下成人中的免疫原性。
Rev Inst Med Trop Sao Paulo. 2024 Apr 19;66:e24. doi: 10.1590/S1678-9946202466024. eCollection 2024.
8
Strategic Planning of a Joint SARS-CoV-2 and Influenza Vaccination Campaign in the UK.英国2019冠状病毒病与流感联合疫苗接种运动的战略规划
Vaccines (Basel). 2024 Feb 3;12(2):158. doi: 10.3390/vaccines12020158.
9
Mathematical Optimization Strategy for Effectiveness Profile Estimation in Two-Dose Vaccines and Its Use in Designing Improved Vaccination Strategies Focused on Pandemic Containment.两剂疫苗有效性评估的数学优化策略及其在设计以大流行防控为重点的改进疫苗接种策略中的应用
Vaccines (Basel). 2024 Jan 12;12(1):81. doi: 10.3390/vaccines12010081.
10
Association between Gross National Income per capita and COVID-19 vaccination coverage: a global ecological study.人均国民总收入与 COVID-19 疫苗接种覆盖率之间的关系：一项全球生态学研究。
BMC Public Health. 2023 Dec 4;23(1):2415. doi: 10.1186/s12889-023-17241-y.
本文引用的文献
1
Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection.一剂 BNT162b2 疫苗可预防无症状 SARS-CoV-2 感染。
Elife. 2021 Apr 8;10:e68808. doi: 10.7554/eLife.68808.
2
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.BNT162b2 mRNA 新冠病毒疫苗在全国大规模疫苗接种环境中的效果。
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
3
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies.全面绘制影响多克隆人血浆抗体识别的 SARS-CoV-2 受体结合域突变图谱。
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6. doi: 10.1016/j.chom.2021.02.003. Epub 2021 Feb 8.
4
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.mRNA 疫苗诱导的针对 SARS-CoV-2 和循环变异株的抗体。
Nature. 2021 Apr;592(7855):616-622. doi: 10.1038/s41586-021-03324-6. Epub 2021 Feb 10.
5
SARS-CoV-2 evolution during treatment of chronic infection.慢性感染治疗过程中 SARS-CoV-2 的进化。
Nature. 2021 Apr;592(7853):277-282. doi: 10.1038/s41586-021-03291-y. Epub 2021 Feb 5.
6
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.基于 rAd26 和 rAd5 载体的异源初免-加强型 COVID-19 疫苗的安全性和有效性：俄罗斯一项随机对照 3 期临床试验的中期分析。
Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2.
7
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.BNT162b2 疫苗诱导的人血清对 SARS-CoV-2 谱系 B.1.1.7 假病毒的中和作用。
Science. 2021 Mar 12;371(6534):1152-1153. doi: 10.1126/science.abg6105. Epub 2021 Jan 29.
8
COVID-19 in Immunocompromised Hosts: What We Know So Far.免疫功能低下宿主中的 COVID-19：目前我们已知的情况。
Clin Infect Dis. 2021 Jan 27;72(2):340-350. doi: 10.1093/cid/ciaa863.
9
Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19).COVID-19 住院患者中感染性病毒排出的持续时间和关键决定因素。
Nat Commun. 2021 Jan 11;12(1):267. doi: 10.1038/s41467-020-20568-4.
10
Covid-19 vaccination: What's the evidence for extending the dosing interval?新冠病毒疫苗接种：延长给药间隔的证据是什么？
BMJ. 2021 Jan 6;372:n18. doi: 10.1136/bmj.n18.
Zotero 插件